Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?

Background: Mid-regional proadrenomedullin (MR-proADM) is a novel biomarker with potential prognostic utility in patients with community-acquired pneumonia (CAP). Purpose: To evaluate the value of MR-proADM levels at ICU admission for further severity stratification and outcome prediction, and its k...

Full description

Bibliographic Details
Main Authors: J.M. Pereira, A. Azevedo, C. Basílio, C. Sousa-Dias, P. Mergulhão, J.A. Paiva
Format: Article
Language:English
Published: Elsevier 2016-11-01
Series:Revista Portuguesa de Pneumologia (English Edition)
Online Access:http://www.sciencedirect.com/science/article/pii/S2173511516300185
id doaj-21f1e32d9c764975ba6d949a5ecef53b
record_format Article
spelling doaj-21f1e32d9c764975ba6d949a5ecef53b2020-11-24T22:12:37ZengElsevierRevista Portuguesa de Pneumologia (English Edition)2173-51152016-11-01226308314Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?J.M. Pereira0A. Azevedo1C. Basílio2C. Sousa-Dias3P. Mergulhão4J.A. Paiva5Emergency and Intensive Care Department, Centro Hospitalar São João EPE, Porto, Portugal; Department of Medicine, University of Porto Medical School, Porto, Portugal; Corresponding author.Hospital Epidemiology Centre, Centro Hospitalar São João EPE, Porto, Portugal; Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical School, Portugal; EPIUnit â Institute of Public Health, University of Porto, PortugalEmergency and Intensive Care Department, Centro Hospitalar São João EPE, Porto, PortugalEmergency and Intensive Care Department, Centro Hospitalar São João EPE, Porto, PortugalEmergency and Intensive Care Department, Centro Hospitalar São João EPE, Porto, Portugal; Department of Medicine, University of Porto Medical School, Porto, PortugalEmergency and Intensive Care Department, Centro Hospitalar São João EPE, Porto, Portugal; Department of Medicine, University of Porto Medical School, Porto, PortugalBackground: Mid-regional proadrenomedullin (MR-proADM) is a novel biomarker with potential prognostic utility in patients with community-acquired pneumonia (CAP). Purpose: To evaluate the value of MR-proADM levels at ICU admission for further severity stratification and outcome prediction, and its kinetics as an early predictor of response in severe CAP (SCAP). Materials and methods: Prospective, single-center, cohort study of 19 SCAP patients admitted to the ICU within 12 h after the first antibiotic dose. Results: At ICU admission median MR-proADM was 3.58 nmol/l (IQR: 2.83â10.00). No significant association was found between its serum levels at admission and severity assessed by SAPS II (Spearman's correlation = 0.24, p = 0.31) or SOFA score (SOFA < 10: <3.45 nmol/l vs. SOFA â¥Â 10: 3.90 nmol/l, p = 0.74). Hospital and one-year mortality were 26% and 32%, respectively. No significant difference in median MR-proADM serum levels was found between survivors and non-survivors and its accuracy to predict hospital mortality was bad (aROC 0.53). After 48 h of antibiotic therapy, MR-proADM decreased in all but 5 patients (median â20%; IQR â56% to +0.1%). Its kinetics measured by the percent change from baseline was a good predictor of clinical response (aROC 0.80). The best discrimination was achieved by classifying patients according to whether MR-proADM decreased or not within 48 h. No decrease in MR-proADM serum levels significantly increased the chances of dying independently of general severity (SAPS II-adjusted OR 174; 95% CI 2â15,422; p = 0.024). Conclusions: In SCAP patients, a decrease in MR-proADM serum levels in the first 48 h after ICU admission was a good predictor of clinical response and better outcome. Keywords: Proadrenomedullin, Biomarkers, Severe community acquired pneumonia, Outcome, Critically ill patientshttp://www.sciencedirect.com/science/article/pii/S2173511516300185
collection DOAJ
language English
format Article
sources DOAJ
author J.M. Pereira
A. Azevedo
C. Basílio
C. Sousa-Dias
P. Mergulhão
J.A. Paiva
spellingShingle J.M. Pereira
A. Azevedo
C. Basílio
C. Sousa-Dias
P. Mergulhão
J.A. Paiva
Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
Revista Portuguesa de Pneumologia (English Edition)
author_facet J.M. Pereira
A. Azevedo
C. Basílio
C. Sousa-Dias
P. Mergulhão
J.A. Paiva
author_sort J.M. Pereira
title Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
title_short Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
title_full Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
title_fullStr Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
title_full_unstemmed Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
title_sort mid-regional proadrenomedullin: an early marker of response in critically ill patients with severe community-acquired pneumonia?
publisher Elsevier
series Revista Portuguesa de Pneumologia (English Edition)
issn 2173-5115
publishDate 2016-11-01
description Background: Mid-regional proadrenomedullin (MR-proADM) is a novel biomarker with potential prognostic utility in patients with community-acquired pneumonia (CAP). Purpose: To evaluate the value of MR-proADM levels at ICU admission for further severity stratification and outcome prediction, and its kinetics as an early predictor of response in severe CAP (SCAP). Materials and methods: Prospective, single-center, cohort study of 19 SCAP patients admitted to the ICU within 12 h after the first antibiotic dose. Results: At ICU admission median MR-proADM was 3.58 nmol/l (IQR: 2.83â10.00). No significant association was found between its serum levels at admission and severity assessed by SAPS II (Spearman's correlation = 0.24, p = 0.31) or SOFA score (SOFA < 10: <3.45 nmol/l vs. SOFA â¥Â 10: 3.90 nmol/l, p = 0.74). Hospital and one-year mortality were 26% and 32%, respectively. No significant difference in median MR-proADM serum levels was found between survivors and non-survivors and its accuracy to predict hospital mortality was bad (aROC 0.53). After 48 h of antibiotic therapy, MR-proADM decreased in all but 5 patients (median â20%; IQR â56% to +0.1%). Its kinetics measured by the percent change from baseline was a good predictor of clinical response (aROC 0.80). The best discrimination was achieved by classifying patients according to whether MR-proADM decreased or not within 48 h. No decrease in MR-proADM serum levels significantly increased the chances of dying independently of general severity (SAPS II-adjusted OR 174; 95% CI 2â15,422; p = 0.024). Conclusions: In SCAP patients, a decrease in MR-proADM serum levels in the first 48 h after ICU admission was a good predictor of clinical response and better outcome. Keywords: Proadrenomedullin, Biomarkers, Severe community acquired pneumonia, Outcome, Critically ill patients
url http://www.sciencedirect.com/science/article/pii/S2173511516300185
work_keys_str_mv AT jmpereira midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia
AT aazevedo midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia
AT cbasalio midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia
AT csousadias midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia
AT pmergulhao midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia
AT japaiva midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia
_version_ 1725803081314074624